scispace - formally typeset
R

Rebecca D. Jackson

Researcher at Ohio State University

Publications -  398
Citations -  56335

Rebecca D. Jackson is an academic researcher from Ohio State University. The author has contributed to research in topics: Women's Health Initiative & Genome-wide association study. The author has an hindex of 88, co-authored 364 publications receiving 50856 citations. Previous affiliations of Rebecca D. Jackson include National Institutes of Health & Brown University.

Papers
More filters
Journal ArticleDOI

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial

TL;DR: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Journal ArticleDOI

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

TL;DR: Estrogen plus progestin therapy increased the risk for probable dementia in postmenopausal women aged 65 years or older and did not prevent mild cognitive impairment in these women, supporting the conclusion that the risks of estrogen plus progESTin outweigh the benefits.
Journal ArticleDOI

Calcium plus vitamin D supplementation and the risk of fractures.

Rebecca D. Jackson, +46 more
TL;DR: Among healthy postmenopausal women, calcium with vitamin D supplementation resulted in a small but significant improvement in hip bone density, did not significantly reduce hip fracture, and increased the risk of kidney stones.
Journal ArticleDOI

Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials

TL;DR: Most risks and benefits dissipated postintervention, although some elevation in breast cancer risk persisted during cumulative follow-up and the 2 WHI hormone therapy trials do not support use of this therapy.